A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS) in Combination With TAK-536 in Subjects With Type II Diabetes.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Azilsartan; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 10 Jun 2017 Biomarkers information updated
- 13 Jan 2009 Planned patient number added (704) as reported by ClinicalTrials.gov.
- 17 Oct 2008 New trial record.